Gsa Capital Partners LLP Amgen Inc Transaction History

Gsa Capital Partners LLP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	BUY	$230.71 - $256.74 $1.05 Million - $1.17 Million	4,538 New	4,538 $1.1 Million
Q4 2021 Feb 14, 2022	SELL	$198.88 - $227.6 $620,704 - $710,339	-3,121 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$212.27 - $248.7 $662,494 - $776,192	3,121 New	3,121 $664,000
Q2 2020 Aug 11, 2020	SELL	$197.81 - $242.74 $387,707 - $475,770	-1,960 Closed	0 $0
Q1 2020 May 12, 2020	SELL	$182.24 - $241.7 $480,749 - $637,604	-2,638 Reduced 57.37%	1,960 $397,000
Q4 2019 Feb 12, 2020	SELL	$189.21 - $243.2 $38,977 - $50,099	-206 Reduced 4.29%	4,598 $1.11 Million
Q3 2019 Nov 12, 2019	SELL	$174.11 - $208.62 $913,729 - $1.09 Million	-5,248 Reduced 52.21%	4,804 $930,000
Q2 2019 Aug 06, 2019	SELL	$166.7 - $195.41 $534,940 - $627,070	-3,209 Reduced 24.2%	10,052 $1.85 Million
Q1 2019 May 15, 2019	BUY	$180.87 - $203.88 $1.28 Million - $1.45 Million	7,094 Added 115.03%	13,261 $2.52 Million
Q4 2018 Feb 12, 2019	SELL	$178.4 - $208.25 $395,334 - $461,482	-2,216 Reduced 26.43%	6,167 $1.2 Million
Q3 2018 Nov 13, 2018	SELL	$185.29 - $208.89 $115,435 - $130,138	-623 Reduced 6.92%	8,383 $1.74 Million
Q2 2018 Aug 09, 2018	SELL	$166.05 - $186.51 $1.52 Million - $1.7 Million	-9,128 Reduced 50.34%	9,006 $1.66 Million
Q1 2018 May 11, 2018	BUY	$169.43 - $198.0 $508,120 - $593,802	2,999 Added 19.81%	18,134 $3.09 Million
Q4 2017 Feb 14, 2018	BUY	$168.79 - $188.59 $1.94 Million - $2.16 Million	11,478 Added 313.86%	15,135 $2.63 Million
Q3 2017 Nov 20, 2017	BUY	$167.29 - $191.0 $611,779 - $698,487	3,657	3,657 $682,000

3,075

417M

7.19M

6.28M

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $169B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.